NEW YORK (GenomeWeb) – Biocept today announced that it has signed two new agreements with preferred provider organization networks — Fortified Provider Network and Three Rivers Provider Network.
Under the deals, the approximately 26 million members of these two PPOs will now have covered access to Biocept's Target Selector non-invasive liquid biopsy assays, which include tests for melanoma, breast, lung, and gastric cancer biomarkers.
Fortified Provider Network is a national direct-contracted PPO used by self-funded employer groups, insurance carriers, and local provider networks. Three Rivers, meanwhile, is one of the largest and fastest growing PPO networks in the nation with 550,000 providers and 5,000 hospitals, according to Biocept.
This September, Biocept signed similar deals with three other PPOs — MultiPlan, Stratose, and Galaxy Health Network.
According to Biocept, its new deals with FPN and Three Rivers bring the total number of consumers with health plan access to its liquid biopsy testing to about 133 million.